CEO David Loew emphasized Ipsen’s sustained growth in 2024, with total sales increasing by 9.9%. He highlighted the strong performance of the ex-Somatuline portfolio, which grew by 12.2% ...

FY 2024 total sales growth of 9.9% at CER 1, or 8.7% as reported, with growth driven by strong performance across all therapeutic areas, including a 67.4% increase in the Rare Diseases portfolio ...

Ms. Ipsen was also recognized by Virginia Business as part of the Virginia 500: Power list and the Women Leadership list. In addition, she was presented a Power of Women award by ASU+GSV in 2021 ...

Ipsen is a growing biopharma company that combines a dynamic, biotech mindset with the resources that come from having 5,400 employees and a direct presence in more than 30 countries. This ...

Ipsen is a global biotechnology company headquartered in France that develops and commercializes medicines across three therapeutic areas: oncology, neuroscience, and rare diseases. Ipsen was ...